Contemporary Management of Respiratory Disorders: Asthma & COPD in Pulmonary Medicine for General Physicians

Abstract

The management of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD) represents a significant clinical challenge due to their rising global prevalence, varying phenotypes, and evolving therapeutic landscape. This review synthesizes the latest evidence on epidemiology, pathophysiology, diagnostic criteria, and current as well as emerging management strategies for asthma and COPD. Emphasis is placed on clinically relevant mechanisms, evidence-based treatment modalities, and guideline-driven recommendations to inform best practices for general physicians and pulmonologists. Recent advances, including biologic therapies, precision medicine approaches, and non-pharmacological interventions, are discussed in the context of improving patient outcomes and addressing disease heterogeneity.

Introduction

Asthma and COPD are the two most prevalent chronic respiratory diseases encountered in clinical practice, contributing significantly to global morbidity, healthcare utilization, and mortality. Both conditions are characterized by airflow limitation but differ in their pathogenesis, clinical course, and therapeutic responses. General physicians play a pivotal role in early diagnosis, management, and long-term follow-up of affected individuals. Understanding the evolving landscape of these disorders, including advances in pathophysiology and therapeutics, is crucial for optimizing patient care and aligning with international guidelines.

Epidemiology / Disease Burden

Asthma affects an estimated 262 million people worldwide, with significant regional disparities influenced by environmental, genetic, and socioeconomic factors. The World Health Organization (WHO) estimates that asthma accounts for approximately 461,000 deaths annually, largely due to inadequate disease control and access to care. COPD, on the other hand, is the third leading cause of death globally, responsible for over 3 million deaths each year. The burden of COPD is projected to increase due to ongoing tobacco use, environmental exposures, and an aging population. Both diseases impose a substantial economic burden on healthcare systems, driven by frequent exacerbations, hospitalizations, and loss of productivity.

Pathophysiology

Asthma is characterized by chronic airway inflammation, reversible airflow obstruction, and bronchial hyperresponsiveness, primarily mediated by type 2 (T2) inflammatory pathways involving eosinophils, mast cells, and Th2 lymphocytes. In contrast, COPD is marked by persistent, largely irreversible airflow limitation resulting from small airway disease, parenchymal destruction (emphysema), and chronic inflammation predominantly involving neutrophils, macrophages, and CD8+ T lymphocytes. Oxidative stress, protease-antiprotease imbalance, and structural remodeling are central to COPD pathogenesis, while genetic predisposition and environmental triggers modulate disease expression in both conditions.

Risk Factors

Asthma risk factors include atopy, family history, early-life respiratory infections, and exposure to allergens or occupational irritants. Urbanization, air pollution, and obesity have emerged as significant contributors in recent years. COPD is strongly associated with cigarette smoking, accounting for up to 85% of cases, but non-smoking-related factors such as biomass fuel exposure, occupational dusts, childhood respiratory infections, genetic factors (e.g., alpha-1 antitrypsin deficiency), and aging also play essential roles. Recognition of modifiable risk factors is critical for prevention and early intervention.

Clinical Features

Asthma typically presents with episodic wheezing, dyspnea, chest tightness, and cough, often with diurnal variation and symptom reversibility. COPD, by contrast, manifests as chronic cough, sputum production, progressive and persistent dyspnea, and exercise intolerance. Exacerbations in both diseases are associated with increased morbidity and accelerated decline in lung function. Overlap syndromes (asthma-COPD overlap, or ACO) present diagnostic and therapeutic complexities due to shared and distinct features.

Diagnosis

Diagnosis of asthma relies on clinical history, demonstration of variable airflow limitation (via spirometry or peak flow monitoring), and response to bronchodilators. Biomarkers such as elevated blood/sputum eosinophils and FeNO measurements can aid in phenotyping. COPD diagnosis is based on post-bronchodilator FEV1/FVC ratio <0.70 and supporting clinical features. Differential diagnosis includes other causes of chronic cough and dyspnea. Assessment of disease severity, control (asthma), and risk stratification (COPD) is essential for personalized management.

Treatment & Management

Asthma management follows a stepwise approach, prioritizing inhaled corticosteroids (ICS) as the cornerstone for persistent disease, with addition of long-acting beta2-agonists (LABA), leukotriene receptor antagonists, or biologics as indicated. Patient education, trigger avoidance, and adherence to inhaler technique are fundamental. COPD management emphasizes smoking cessation, pulmonary rehabilitation, vaccination, and pharmacotherapy tailored to symptoms and exacerbation risk. Long-acting bronchodilators (LAMA, LABA), with or without ICS, form the therapeutic backbone. Acute exacerbations require prompt escalation of therapy, often with short courses of systemic corticosteroids and antibiotics.

Recent Advances / Emerging Therapies

Biologic agents targeting IgE (omalizumab), IL-5 (mepolizumab, reslizumab, benralizumab), and IL-4/IL-13 (dupilumab) have transformed severe asthma management, enabling precision therapy for T2-high endotypes. In COPD, phosphodiesterase-4 inhibitors (roflumilast), triple inhaled therapy, and novel anti-inflammatory agents are under investigation. Non-pharmacological advances include digital health interventions, home-based monitoring, and bronchoscopic lung volume reduction for selected COPD phenotypes. Ongoing research into genetic, epigenetic, and microbiome influences promises to further individualize care.

Guideline Recommendations

Current Global Initiative for Asthma (GINA) guidelines advocate early initiation of ICS in all asthma patients with persistent symptoms, recommend as-needed low-dose ICS-formoterol for mild asthma, and stress regular assessment of control and comorbidities. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines stratify COPD patients by symptoms and exacerbation history, guiding escalation from monotherapy to dual or triple therapy, and emphasizing non-pharmacological interventions. Both guidelines underscore the importance of personalized care, risk reduction, and multidisciplinary management to optimize outcomes.

Conclusion

Effective management of asthma and COPD hinges on accurate diagnosis, phenotypic characterization, and evidence-based, individualized therapy. Recent advances in biologics and targeted interventions offer hope for improved disease control and quality of life. General physicians must remain updated on evolving guidelines and emerging therapies to provide optimal, holistic care for patients with chronic respiratory diseases. Future research will continue to refine our understanding of disease mechanisms and expand the therapeutic armamentarium, with the ultimate goal of reducing the global burden of respiratory morbidity and mortality.